ATE313332T1 - Chaperonin 10 und beta-interferon therapie für multiple sklerose - Google Patents

Chaperonin 10 und beta-interferon therapie für multiple sklerose

Info

Publication number
ATE313332T1
ATE313332T1 AT00903434T AT00903434T ATE313332T1 AT E313332 T1 ATE313332 T1 AT E313332T1 AT 00903434 T AT00903434 T AT 00903434T AT 00903434 T AT00903434 T AT 00903434T AT E313332 T1 ATE313332 T1 AT E313332T1
Authority
AT
Austria
Prior art keywords
beta
multiple sclerosis
chaperonine
interferon therapy
chaperonin
Prior art date
Application number
AT00903434T
Other languages
German (de)
English (en)
Inventor
Halle Morton
Alice Cavanagh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Application granted granted Critical
Publication of ATE313332T1 publication Critical patent/ATE313332T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Surgical Instruments (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00903434T 1999-01-20 2000-01-20 Chaperonin 10 und beta-interferon therapie für multiple sklerose ATE313332T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP8239A AUPP823999A0 (en) 1999-01-20 1999-01-20 A treatment
PCT/AU2000/000032 WO2000043033A1 (en) 1999-01-20 2000-01-20 CHAPERONIN 10 AND β-INTERFERON THERAPY OF MULTIPLE SCLEROSIS

Publications (1)

Publication Number Publication Date
ATE313332T1 true ATE313332T1 (de) 2006-01-15

Family

ID=3812443

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00903434T ATE313332T1 (de) 1999-01-20 2000-01-20 Chaperonin 10 und beta-interferon therapie für multiple sklerose

Country Status (12)

Country Link
US (1) US20090214473A1 (cg-RX-API-DMAC10.html)
EP (1) EP1150703B1 (cg-RX-API-DMAC10.html)
JP (1) JP4691257B2 (cg-RX-API-DMAC10.html)
KR (1) KR100694011B1 (cg-RX-API-DMAC10.html)
AT (1) ATE313332T1 (cg-RX-API-DMAC10.html)
AU (2) AUPP823999A0 (cg-RX-API-DMAC10.html)
CA (1) CA2361081C (cg-RX-API-DMAC10.html)
DE (1) DE60024967T2 (cg-RX-API-DMAC10.html)
DK (1) DK1150703T3 (cg-RX-API-DMAC10.html)
ES (1) ES2255484T3 (cg-RX-API-DMAC10.html)
PT (1) PT1150703E (cg-RX-API-DMAC10.html)
WO (1) WO2000043033A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007517808A (ja) * 2004-01-16 2007-07-05 キュビオ リミテッド Ｔｏｌｌ様受容体誘導性のサイトカインおよびケモカイン分泌のシャペロニン１０調節
BG66458B1 (bg) * 2005-03-21 2014-10-31 Иван Иванов Средство за конкурентно инхибиране на ендогенен гама интерферон
EP2463307A1 (en) 2005-08-31 2012-06-13 CBIO Limited Modified chaperonin 10
CA2626692A1 (en) * 2005-10-20 2007-04-26 Cbio Limited Treatment of hypersensitivity
MX2008011167A (es) * 2006-03-02 2008-11-12 Cbio Ltd Regulaciòn de respuestas inmunes mediante la modulaciòn de la funciòn de cèlulas presentadoras de antìgenos.
BG66517B1 (bg) 2008-04-08 2016-02-29 Tigo Gmbh Супресор на ендогенния човешки гама - интерферон
US9359421B2 (en) 2008-04-08 2016-06-07 Tigo Gmbh Suppressor of the endogenous interferon-gamma
BG1430U1 (bg) * 2010-06-25 2011-04-29 Иван ИВАНОВ Фармацевтично средство
BG67190B1 (bg) 2017-03-29 2020-11-16 Tigo Gmbh Анти-гама мутантен протеин срещу ендогенния човешки гама интерферон

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015338A1 (en) * 1993-11-30 1995-06-08 The University Of Queensland Chaperonin 10
JPH10500109A (ja) * 1994-05-10 1998-01-06 イミユロジク・フアーマシユーチカル・コーポレーシヨン 多発性硬化症のための組成物および治療方法
DE19544768C1 (de) * 1995-11-30 1997-07-10 Rentschler Arzneimittel Verwendung einer Kombination aus Pentoxifyllin mit Typ-I-Interferonen zur Behandlung der Multiplen Sklerose

Also Published As

Publication number Publication date
CA2361081C (en) 2010-09-21
KR20020002376A (ko) 2002-01-09
EP1150703A1 (en) 2001-11-07
DE60024967T2 (de) 2006-08-17
CA2361081A1 (en) 2000-07-27
KR100694011B1 (ko) 2007-03-12
AU2527100A (en) 2000-08-07
EP1150703A4 (en) 2004-11-10
ES2255484T3 (es) 2006-07-01
JP4691257B2 (ja) 2011-06-01
WO2000043033A1 (en) 2000-07-27
PT1150703E (pt) 2006-05-31
JP2002535286A (ja) 2002-10-22
US20090214473A1 (en) 2009-08-27
DE60024967D1 (en) 2006-01-26
DK1150703T3 (da) 2006-05-29
AU771867B2 (en) 2004-04-01
EP1150703B1 (en) 2005-12-21
AUPP823999A0 (en) 1999-02-11

Similar Documents

Publication Publication Date Title
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
CY1107995T1 (el) ΑΝΑΣΤΟΛΗ ΔΡΑΣΤΙΚΟΤΗΤΑΣ p38 ΚΙΝΑΣΗΣ ΧΡΗΣΙΜΟΠΟΙΩΝΤΑΣ ΑΡΥΛ ΚΑΙ ΕΤEPΟΑΡΥΛ ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΕΤEPΟΚΥΚΛΙΚΕΣ ΟΥΡΙΕΣ
DE69526120D1 (de) Verwendung von nebivolol als anti-atherogenisches mittel
IL178072A0 (en) Use of monoesters of probucol or a pharmaceutically acceptable salt thereof for preparing medicaments for the treatment of cardiovascular disease
ES2151467T1 (es) Inhibicion de la actividad de la quinasa p38 por aril-ureas.
ATE232396T1 (de) Oxydiertes thymosin beta 4
HUT76258A (en) Compositions comprising dna damaging agents and p53, and methods for uses thereof
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
DE69830512D1 (de) Heilmittel für neurodegenerative krankheiten
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
NO972391D0 (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
AR034343A1 (es) Combinaciones farmaceuticas
ATE82127T1 (de) N-acetylglucosamin-zubereitungen zur buccalen anwendung.
RU95106680A (ru) Бициклические ароматические соединения и содержащие их фармацевтические и косметические композиции
GEP20002092B (en) 5,6-Dihydropyrone Derivatives Pharma¬ceutical Compositions on the Base of them and Method for Treatment of Antiviral diseases
EP1150703A4 (en) CHAPERONIN 10 AND BETA INTERFERON THERAPY FOR MULTIPLE Sclerosis
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
DE69612056D1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
TR199901385T2 (xx) Piperidin t�revleri.
FI922428A0 (fi) Nya 2-amino-5-cyan-1,4- dihydropyridiner, foerfarande foer deras framstaellning och deras anvaendning i laekemedel.
DE69314586D1 (de) Arzneimittelzusammensetzung enthaltend TCF-II
TR200003352T2 (tr) Yeni pentaerythrit türevleri, bunların imalatı ve kullanımları ile bunların sentezi için ara maddeler
SE9902673D0 (sv) New composition

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties